Digital Therapeutics Platform Competition Issues

Introduction

Digital therapeutics (DTx) are software-based interventions designed to prevent, manage, or treat medical conditions. They may operate through smartphone applications, connected devices, clinical platforms, wearable technologies, remote-monitoring systems, or AI-enabled therapeutic programs. Unlike ordinary wellness applications, digital therapeutics are generally intended to produce clinically meaningful therapeutic outcomes and may be subject to medical-device, healthcare, reimbursement, privacy, and professional-regulation requirements.

Competition concerns arise because DTx platforms often combine several forms of market power: clinical data, proprietary algorithms, app ecosystems, healthcare-provider networks, reimbursement relationships, interoperability standards, and access to patients. A platform that controls one layer can potentially leverage that position into adjacent markets.

The principal competition-law question is therefore not simply whether a DTx provider charges excessive prices. It is whether control over data, distribution, standards, devices, clinical integration, or reimbursement allows a firm to exclude rivals or reduce effective competition.

1. Meaning and Structure of Digital Therapeutics Platform Competition

A typical DTx ecosystem may contain:

1. Patients – users receiving therapeutic interventions.
2. DTx developers – companies developing therapeutic software.
3. Healthcare providers – doctors, hospitals and clinics prescribing or supervising treatment.
4. Platforms – app stores, operating systems, cloud services and digital-health marketplaces.
5. Device manufacturers – wearable, sensor and diagnostic-device companies.
6. Insurers and public payers – entities determining reimbursement.
7. Pharmacies and pharmaceutical companies – potential complementary or competing therapeutic channels.
8. Data providers – providers of clinical, behavioural and physiological information.
9. Regulators and standards bodies – institutions determining certification, safety and interoperability.

Competition can therefore occur within DTx products as well as between DTx and conventional treatments.

2. Relevant Markets

Competition analysis may involve several overlapping markets.

A. DTx product market

The relevant market could be treatment-specific, such as:

• digital diabetes management;
• digital insomnia treatment;
• digital cognitive behavioural therapy;
• digital substance-use treatment;
• digital rehabilitation.

B. Platform market

A platform may provide:

• patient acquisition;
• prescription management;
• provider dashboards;
• payment;
• reimbursement;
• clinical-data integration.

C. Data market

Valuable datasets may include:

• treatment outcomes;
• patient adherence;
• physiological measurements;
• behavioural patterns;
• clinical histories.

D. Distribution market

App stores, operating systems and healthcare marketplaces can constitute important distribution channels.

E. Complementary technology markets

Competition can also concern:

• cloud infrastructure;
• APIs;
• wearable operating systems;
• health-data interoperability;
• electronic health-record integration.

The relevant market should not automatically be defined as "digital therapeutics." The appropriate definition depends upon substitutability, therapeutic purpose, regulation, reimbursement, switching costs and clinical effectiveness.

3. Network Effects

DTx platforms can exhibit strong direct and indirect network effects.

More patients can attract more healthcare providers. More providers can attract more patients. More users generate additional data, which may improve algorithms. Better algorithms can attract still more users.

This creates a feedback loop:

More users → more data → better product → more providers → more users

A dominant platform may therefore become increasingly difficult to challenge even where competing technology is available.

Competition authorities may consequently examine dynamic competition, rather than merely current prices.

4. Data Accumulation and Data Advantage

Clinical and behavioural data can constitute an important competitive asset.

A DTx incumbent may accumulate:

• longitudinal patient histories;
• adherence data;
• treatment-response data;
• biometric information;
• clinical outcomes;
• physician feedback.

A rival entering the market may lack comparable datasets.

The competition concern becomes particularly serious where the incumbent:

• prevents users from exporting their data;
• restricts API access;
• prevents interoperability;
• combines DTx data with data from other services;
• uses exclusive agreements to acquire datasets.

Data advantage does not automatically equal dominance. The relevant question is whether the data are non-replicable, competitively significant and capable of supporting exclusionary conduct.

5. Self-Preferencing

A healthcare platform may simultaneously operate:

• a DTx marketplace;
• a healthcare-provider platform;
• an app store;
• a competing DTx product.

It may then give preferential treatment to its own therapeutic application.

Examples include:

• higher search rankings;
• preferential recommendation;
• pre-installation;
• privileged access to APIs;
• better integration with wearable devices;
• preferential reimbursement placement.

The competitive concern is vertical leveraging: platform power at one level is used to advantage a related product.

6. Exclusive Dealing

A dominant DTx platform could require:

• hospitals to use only its software;
• insurers to reimburse only its platform;
• doctors to prescribe exclusively through its system;
• wearable manufacturers to integrate exclusively with its application.

Exclusive dealing may reduce rivals' access to essential distribution channels.

The legal assessment normally depends upon:

• duration;
• market coverage;
• foreclosure percentage;
• switching costs;
• entry barriers;
• availability of alternatives;
• efficiency justifications.

7. Interoperability Restrictions

Interoperability is especially important in digital healthcare.

A DTx provider might restrict interoperability with:

• electronic health records;
• competing wearable devices;
• competing DTx applications;
• hospital information systems;
• insurance platforms.

This can create technical lock-in.

For example:

Patient → DTx Platform A → proprietary data format → Hospital

If Platform A refuses to allow the patient or hospital to transfer information to Platform B, switching becomes expensive.

Competition law may therefore intersect with data portability and essential-facility principles.

8. Tying and Bundling

A large digital-health company might bundle:

DTx software + wearable device + cloud infrastructure + physician platform

and condition access to one component upon purchase or use of another.

The concern is that a firm with substantial market power in one component can use bundling to extend that power into adjacent markets.

However, integration may also produce legitimate efficiencies, such as:

• improved clinical safety;
• reduced latency;
• better cybersecurity;
• better patient monitoring.

Consequently, competition authorities must distinguish anticompetitive foreclosure from genuine technical integration.

9. App-Store Gatekeeping

Many DTx applications depend upon mobile operating systems and app stores.

Potential competition problems include:

• discriminatory app-store commissions;
• restrictions on alternative payment systems;
• restrictions on external subscriptions;
• limitations on health-data APIs;
• discriminatory review processes;
• preferential treatment for platform-owned health products.

The issue becomes particularly important where the app-store operator also competes with DTx developers.

10. Algorithmic Discrimination

DTx platforms increasingly use AI to:

• determine treatment pathways;
• personalize interventions;
• recommend providers;
• predict adherence;
• determine patient risk;
• allocate healthcare resources.

A platform could potentially manipulate algorithms to disadvantage rival products.

For example, its recommendation engine could systematically place its own therapeutic product above competitors despite comparable clinical performance.

Competition authorities may need to examine:

• ranking algorithms;
• recommendation criteria;
• training data;
• treatment outcomes;
• unexplained changes in ranking.

11. Algorithmic Collusion

Multiple DTx platforms may use automated pricing or contracting systems.

If competing platforms use algorithms capable of rapidly responding to each other's prices, prices could become aligned without conventional human communication.

The central legal issue is whether the conduct amounts to:

• an express agreement;
• coordinated conduct;
• conscious parallelism;
• hub-and-spoke coordination; or
• independent algorithmic behaviour.

The mere use of similar algorithms does not automatically establish a cartel.

12. Patient Switching Costs

Switching can be costly because patients may have accumulated:

• treatment histories;
• personalized settings;
• behavioural records;
• wearable integrations;
• physician connections;
• subscription benefits.

This can create digital therapeutic inertia.

A platform may strengthen this inertia through:

• proprietary data formats;
• difficult cancellation;
• non-portable treatment histories;
• incompatible devices;
• contractual restrictions.

High switching costs can reduce contestability, even where nominally competing DTx platforms exist.

13. Reimbursement and Payer Foreclosure

Healthcare markets have an unusual feature: the person receiving the service is often not the person paying for it.

Insurance companies and public healthcare systems may therefore determine which DTx products survive.

A dominant DTx provider could seek exclusive reimbursement arrangements.

Potential effects include:

• foreclosure of smaller competitors;
• reduced innovation;
• higher reimbursement prices;
• reduced therapeutic choice.

Competition authorities may need to consider both competition among DTx providers and competition for payer contracts.

14. Mergers and Acquisitions

DTx markets can be vulnerable to acquisitions of emerging competitors.

A dominant healthcare platform might acquire a promising DTx startup before it becomes a serious competitor.

Traditional turnover thresholds may underestimate the importance of such acquisitions where startups possess:

• valuable clinical datasets;
• innovative algorithms;
• patents;
• highly engaged patient communities;
• unique provider relationships.

Thus, merger review may need to examine innovation competition, not merely current revenues.

15. Killer Acquisitions

A large platform might acquire an emerging DTx company primarily to neutralize future competition.

For example:

Incumbent DTx platform → acquires innovative insomnia-treatment startup → discontinues competing technology

The immediate market-share effect might appear small, but the acquisition could eliminate a future source of innovation.

Relevant merger analysis may therefore examine:

• pipeline products;
• R&D capabilities;
• clinical trials;
• intellectual property;
• developer talent;
• potential competitive constraints.

16. Excessive Pricing

A dominant DTx provider could potentially charge excessive prices to:

• insurers;
• healthcare systems;
• employers;
• patients.

However, excessive-pricing analysis is difficult because DTx companies may legitimately need to recover:

• clinical-trial costs;
• regulatory-compliance costs;
• cybersecurity expenditure;
• software development;
• clinical validation.

Consequently, high prices alone do not establish an abuse of dominance.

17. Predatory Pricing

A large platform could subsidize DTx services below cost to eliminate smaller rivals.

For example:

Large ecosystem → free DTx application → competitor exits → prices subsequently increase

The analysis would consider:

• pricing below relevant cost benchmarks;
• ability to recoup losses;
• exclusionary intent/effect;
• duration;
• market structure.

The multi-sided nature of digital platforms makes traditional cost tests particularly complicated.

18. Refusal to Supply Data or APIs

A dominant DTx platform may control access to:

• patient data;
• clinical APIs;
• wearable-device interfaces;
• treatment-management APIs.

A refusal to provide access can become a competition concern where rivals cannot realistically compete without the relevant input.

This invokes principles associated with essential facilities and refusal-to-deal jurisprudence, although the legal threshold for compulsory access is generally demanding.

19. Privacy as a Competition Parameter

Privacy can itself constitute a dimension of competition.

Two DTx platforms may provide similar therapeutic services but differ substantially in:

• data collection;
• data sharing;
• advertising practices;
• retention periods;
• secondary data use.

A dominant platform could worsen privacy conditions because users have insufficient alternatives.

Thus, competition authorities increasingly consider quality, privacy and innovation, rather than price alone.

20. Six Important Case Laws

1. FTC v. Surescripts, LLC

The Surescripts litigation concerned competition in electronic prescribing services and allegations involving exclusionary contracting practices.

Significance

It demonstrates how healthcare technology platforms can acquire or preserve market power through contractual arrangements with participants in a digital healthcare network.

DTx relevance

The principles are relevant where a DTx platform uses:

• exclusivity;
• loyalty arrangements;
• provider contracts;
• payer relationships

to prevent rival therapeutic platforms from obtaining sufficient scale.

2. United States v. Microsoft Corp.

The Microsoft litigation is one of the foundational cases concerning technological platform power, tying and exclusionary conduct.

Principle

A company possessing substantial power in one technological layer may unlawfully use that power to restrict competition in adjacent markets.

DTx relevance

The analogy is particularly strong for:

Operating system → app distribution → DTx application

or:

Healthcare platform → clinical integration → DTx service

The case demonstrates why competition authorities examine platform architecture and leveraging, rather than isolated product pricing.

3. United States v. Google LLC

The Google search-advertising litigation illustrates the competition concerns associated with control over digital distribution, defaults and access points.

DTx relevance

Similar concerns could arise where a dominant digital-health ecosystem controls:

• search;
• app discovery;
• default applications;
• recommendations;
• healthcare advertising.

If a platform systematically directs patients toward its own DTx product, self-preferencing and foreclosure concerns may arise.

4. Google Android – European Commission

The European Commission's Android decision addressed Google's practices concerning mobile operating systems, app stores and related services.

Competition principle

A firm controlling a critical technological ecosystem may have incentives and opportunities to extend its power into adjacent markets through:

• tying;
• contractual restrictions;
• default arrangements;
• ecosystem control.

DTx relevance

The case is highly relevant to DTx because healthcare applications frequently depend upon mobile ecosystems.

Potential analogous conduct includes restricting:

• health APIs;
• alternative payment systems;
• competing applications;
• wearable integrations.

5. Slovak Telekom a.s. v European Commission

The Court of Justice considered exclusionary conduct involving access to telecommunications infrastructure and the relationship between dominance and access obligations.

DTx relevance

The case provides useful principles for analysing situations in which a dominant digital-health platform controls infrastructure needed by competitors.

Possible examples include:

• proprietary clinical APIs;
• patient-data interfaces;
• healthcare-network infrastructure;
• device interoperability.

It is particularly useful for distinguishing ordinary commercial freedom from circumstances in which refusal of access may have competition-law consequences.

6. Bronner v Mediaprint

Oscar Bronner GmbH & Co. KG v Mediaprint Zeitungs und Zeitschriftenverlag GmbH & Co. KG is a leading EU case concerning refusal to provide access to infrastructure.

Principle

Compulsory access under the essential-facilities/refusal-to-deal doctrine requires stringent conditions.

DTx relevance

A DTx platform should not automatically be required to share every database, algorithm or interface.

The relevant questions include:

1. Is the facility genuinely indispensable?
2. Can a rival realistically reproduce or obtain an alternative?
3. Would refusal eliminate effective competition?
4. Is access technically and commercially feasible?
5. Is there an objective justification for refusal?

21. Additional Relevant Case Laws

7. IMS Health GmbH & Co. KG v NDC Health

This case concerned access to a protected structure/data format in the pharmaceutical information sector.

Relevance

It is particularly important for DTx because digital healthcare may involve proprietary data structures and interoperability standards.

The case demonstrates the tension between:

intellectual-property rights + interoperability + competition

8. Magill

The Magill litigation established important principles concerning exceptional circumstances in which refusal to license intellectual property may raise competition concerns.

DTx relevance

A DTx firm might hold patents or proprietary technology covering:

• therapeutic algorithms;
• interoperability standards;
• device interfaces.

However, compulsory licensing remains exceptional rather than automatic.

9. Aspen Skiing Co. v Aspen Highlands Skiing Corp.

This US Supreme Court case concerned a refusal to continue a previously profitable cooperative arrangement.

DTx relevance

It can inform analysis of situations where a dominant DTx provider:

• previously interoperated with rivals;
• shared certain data or APIs;
• later withdraws access;
• does so without legitimate business justification.

The factual context is different, but the case is useful for understanding the significance of termination of prior cooperation.

10. Qualcomm Inc. v FTC

The Qualcomm litigation addressed competition issues surrounding licensing, technology markets and exclusionary strategies.

DTx relevance

It is relevant to DTx ecosystems where firms control patented technologies used by:

• medical devices;
• sensors;
• communications systems;
• therapeutic software.

It demonstrates the importance of carefully distinguishing legitimate intellectual-property monetisation from conduct that unlawfully excludes competitors.

22. Competition Issues in a DTx Ecosystem

23. Regulatory Tension: Competition vs Patient Safety

DTx competition law cannot be separated completely from healthcare regulation.

A platform may justify exclusivity or interoperability restrictions by claiming:

• patient safety;
• cybersecurity;
• clinical validation;
• regulatory compliance;
• protection against malfunction;
• data integrity.

These can constitute legitimate objectives.

Competition authorities must therefore ask:

Is the restriction genuinely necessary for safety, or is safety being used as a pretext for protecting market power?

This distinction is particularly important because overly aggressive interoperability mandates could themselves create safety risks.

24. Innovation Competition

Innovation is perhaps the most important long-term competition parameter in DTx.

A market can appear competitive today while becoming less competitive tomorrow if dominant platforms acquire or suppress innovative entrants.

Competition analysis should therefore examine:

• R&D pipelines;
• clinical trials;
• emerging therapeutic models;
• AI capabilities;
• patient engagement technologies;
• interoperability innovations;
• future treatment substitutes.

A DTx platform's competitive significance may therefore be much greater than its current revenue suggests.

25. Remedies

Competition authorities may employ several remedies.

Structural remedies

• divestiture;
• separation of platform and DTx operations;
• prohibition of acquisitions.

Behavioural remedies

• non-discrimination;
• interoperability;
• API access;
• data portability;
• prohibition of exclusive contracts;
• transparent ranking criteria.

Data remedies

• patient-controlled portability;
• standardized data formats;
• interoperability obligations;
• restrictions on combining datasets.

Merger remedies

• licensing;
• continued access to APIs;
• preservation of R&D projects;
• non-discriminatory access to healthcare networks.

26. Key Legal Test

A useful analytical framework is:

Step 1 — Define the market
↓
Step 2 — Determine market power
↓
Step 3 — Identify the platform's control point
↓
Step 4 — Identify exclusionary conduct
↓
Step 5 — Establish actual or likely foreclosure
↓
Step 6 — Examine effects on price, quality, privacy, choice and innovation
↓
Step 7 — Assess objective justifications and efficiencies
↓
Step 8 — Determine proportionate remedy

Conclusion

Digital therapeutics create a distinctive competition-law environment because healthcare, software, data and platform economics converge in a single ecosystem.

The most significant risks are not limited to traditional price-based conduct. They include data accumulation, patient lock-in, interoperability restrictions, self-preferencing, exclusive healthcare contracts, app-store gatekeeping, algorithmic discrimination, strategic acquisitions and control over clinical distribution channels.

The central competition-policy challenge is to preserve contestability and innovation without undermining clinical safety. Cases such as Microsoft, Google Android, Bronner, IMS Health, Magill, Aspen Skiing, Surescripts and Qualcomm provide useful doctrinal foundations, although none is a perfect one-to-one DTx precedent.